<DOC>
	<DOCNO>NCT00433095</DOCNO>
	<brief_summary>1st-line treatment HER2/neu overexpressing breast cancer</brief_summary>
	<brief_title>Vinorelbine ( Oral ) Plus Trastuzumab 1st-line Treatment HER2/Neu Overexpressing Breast Cancer</brief_title>
	<detailed_description>The combination vinorelbine trastuzumab demonstrate highly effective several trial show response rate range 59-78 % . This combination characterize good tolerability apply prolonged period without risk major cumulative toxicity The availability oral vinorelbine promise simplification therapy . The present trial therefore investigate safety efficacy combine treatment trastuzumab oral vinorelbine .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically proven , metastatic breats cancer . HER2neu overexpression ( IHC3+ IHC2+/FISH+ ) Written inform consent previous therapy vinorelbine trastuzumab Age * 18 * 75 year KarnofskyPerformance status &gt; 70 % Life expectance 16 week Availability least one target lesion accord RECISTcriteria . Target lesion need outside radiation field . Bone metastases excluded indicator leasions Exclusion pregnancy adequte contraception childbearing age . Adequate hematological , renal , hepatic function Normal cardiac function . LVEF &gt; 10 % normal . Adequate compliance perform treatment subsequent followup visit Locoregional recurrence breast cancer development contralateral breast cancer Pregnancy lactation Symptomatic brain meningeal metastasis Concurrent endocrine antitumor therapy Other malignancy except basal cell cancer skin insitu carcinoma cervix Peripheral neuropathy &gt; = NCI CTC Grade 2. severel disease preclude adequate treatment Participation clinical trial within last 30 day . Psychological , familial , sociological geographical condition preclude treatment accord protocol plan followup</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Navelbine</keyword>
	<keyword>Herceptin</keyword>
	<keyword>oral</keyword>
	<keyword>breast cancer</keyword>
</DOC>